Watch for the separate Phase II CVID topline results expected in November 2026, which will inform plans for a potential registrational study. Positive CVID data would significantly expand the commercial opportunity for leniolisib beyond the current APDS indication.
Price Chart
Executive Summary
Pharming Group N.V. announced positive Phase II topline data for leniolisib in genetic primary immunodeficiencies (PIDs) with immune dysregulation, presented at ESID 2026. The single-arm, open-label study (n=13) showed improvements in lymphoproliferation (spleen volume -26.4%, lymph node size -33.7%), pulmonary function (DLCO +8.0%), and liver stiffness, with all 12 completers enrolling in a long-term extension. These data expand leniolisib's potential addressable market beyond APDS (1.5 patients per million) to genetic PIDs (~7.5/million) and CVID (~39/million), with a separate Phase II CVID topline expected in November 2026.
Key Facts
- Phase II topline data for leniolisib in genetic PIDs with immune dysregulation presented at ESID 2026
- Single-arm, open-label, dose-escalation study enrolled 13 participants with CTLA4, SOCS1, NFKB1, or FAS gene variants
- Spleen volume mean reduction of 26.4% (n=11), with reductions in 10 of 11 evaluable participants
- Lymph node index lesion size mean reduction of 33.7% (n=4), reductions in all four evaluable participants
- Among participants with impaired gas exchange at baseline (n=7), DLCO increased by mean of 8.0%
- All 12 participants who completed the study enrolled in a three-year extension study (NCT06990529)
- Estimated prevalence: genetic PIDs ~7.5 patients per million, CVID ~39 per million, vs APDS ~1.5 per million
- Topline results from separate Phase II trial in CVID expected in November 2026
Financial Impact
No financial figures provided in the filing. The data expands the potential addressable market for leniolisib from APDS (~1.5/million) to genetic PIDs (~7.5/million) and CVID (~39/million), but no revenue, costs, or deal values were disclosed.
Risk Factors
- Small sample size (n=13) limits statistical robustness of the Phase II data
- Single-arm, open-label design introduces potential bias
- CVID topline results in November 2026 are a binary catalyst — negative data would derail the broader strategy
- Leniolisib safety and efficacy not yet established for these investigational uses beyond APDS
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001828316-26-000045 |
| Document: 0001828316-26-000045-index-headers.html | 0001828316-26-000045 |
| Document: 0001828316-26-000045-index.html | 0001828316-26-000045 |
| Document: 0001828316-26-000045.txt | 0001828316-26-000045 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $11.55 | awaiting T+1 | — | $11.87 (+2.77%) |
Oct 27, 2026 today | Press Release | $11.55 | awaiting T+1 | — | $11.87 (+2.77%) |
Oct 22, 2026 5d ago | 6-K | $10.67 $11.20 | ▲ +4.97% | ▲ +5.49% | $11.87 (+11.25%) |
Oct 14, 2026 13d ago | 6-K | $9.64 $9.63 | ▼ −0.10% | ▼ −0.39% | $11.87 (+23.13%) |
Sep 29, 2026 28d ago | 6-K | $10.01 $9.99 | ▲ +0.20% | ▼ −0.01% | $11.87 (−18.58%) |
Sep 29, 2026 28d ago | Press Release | $10.01 $9.99 | ▲ +0.20% | ▼ −0.01% | $11.87 (−18.58%) |
Sep 25, 2026 4w ago | 6-K | $10.46 $10.52 | ▲ +0.57% | ▲ +1.32% | $11.87 (+13.48%) |
Sep 25, 2026 4w ago | Press Release | $10.46 $10.52 | ▲ +0.57% | ▲ +1.32% | $11.87 (+13.48%) |
Sep 22, 2026 5w ago | 6-K | $11.26 $10.77 | ▼ −4.35% | ▼ −3.63% | $11.87 (+5.42%) |
Sep 11, 2026 6w ago | 6-K | $11.21 $10.82 | ▼ −3.48% | ▼ −3.03% | $11.87 (+5.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers